Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Riyao Yang"'
Autor:
Riyao Yang, Su Huang, Cai Huang, Nathan S. Fay, Yanan Wang, Saroja Putrevu, Kimberly Wright, Mohd Saif Zaman, Wenyan Cai, Betty Huang, Bo Wang, Meredith Wright, Matthew R. Hoag, Allison Titong, Yue Liu
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract The landscape of current cancer immunotherapy is dominated by antibodies targeting PD-1/PD-L1 and CTLA-4 that have transformed cancer therapy, yet their efficacy is limited by primary and acquired resistance. The blockade of additional immun
Externí odkaz:
https://doaj.org/article/079a39b41a854fccb3850dced3f2c63c
Autor:
Riyao Yang, Linlin Sun, Ching-Fei Li, Yu-Han Wang, Jun Yao, Hui Li, Meisi Yan, Wei-Chao Chang, Jung-Mao Hsu, Jong-Ho Cha, Jennifer L. Hsu, Cheng-Wei Chou, Xian Sun, Yalan Deng, Chao-Kai Chou, Dihua Yu, Mien-Chie Hung
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Galectin-9 regulates several cellular processes including TIM-3-mediated T cell death. Here the authors show that co-expressed PD-1 protects TIM-3+ T cells from galectin-9-induced cell death and that anti-galectin-9 in combination with GITR agonism p
Externí odkaz:
https://doaj.org/article/d523a90c2f74464eb447b3b58eea546f
Autor:
Shuang Zheng, Jiaming Song, Dongli Linghu, Riyao Yang, Boning Liu, Zhen Xue, Qihui Chen, Chengjie Liu, Diansheng Zhong, Mien-Chie Hung, Linlin Sun
Publikováno v:
International Journal of Biological Sciences. 19:981-993
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa1efa071540fd24b00d33f9f1e5cc4b
https://doi.org/10.7150/ijbs.79852
https://doi.org/10.7150/ijbs.79852
Autor:
Mien-Chie Hung, Dihua Yu, Haoqiang Ying, Shuqun Zhang, Jingkun Qu, Li-Chuan Chan, Riyao Yang, Wei-Chao Chang, Jennifer L. Hsu, Chunxiao Liu, Zhou Jiang, Jung-Mao Hsu, Yintao Li, Yu-Yi Chu, Yongkun Wei, Xixi Zhao
Targeting immune checkpoints such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has transformed cancer treatment, with durable clinical responses across a wide range of tumor types. However, a high percentage of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ecd668b5ac54ec7cede757aa3499aee
https://doi.org/10.1158/0008-5472.c.6513784
https://doi.org/10.1158/0008-5472.c.6513784
Autor:
Xian Sun, Wei-Jan Wang, Jilu Lang, Riyao Yang, Wan-Jou Shen, Linlin Sun, Jung-Mao Hsu, Li-Chuan Chan, Chia-Wei Li, Weiya Xia, Baozhen Ke, Guodong Yao, Kebin Huang, Pei-Chih Lee, Koller, Paul B., Mien-Chie Hung
Publikováno v:
International Journal of Biological Sciences; 2023, Vol. 19 Issue 14, p4644-4656, 13p
Autor:
Xixi Zhao, Yongkun Wei, Yu-Yi Chu, Yintao Li, Jung-Mao Hsu, Zhou Jiang, Chunxiao Liu, Jennifer L. Hsu, Wei-Chao Chang, Riyao Yang, Li-Chuan Chan, Jingkun Qu, Shuqun Zhang, Haoqiang Ying, Dihua Yu, Mien-Chie Hung
Publikováno v:
Cancer research. 82(11)
Targeting immune checkpoints such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has transformed cancer treatment, with durable clinical responses across a wide range of tumor types. However, a high percentage of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ef63916c46c6d9756660974fcfd47e
https://pubmed.ncbi.nlm.nih.gov/35385574
https://pubmed.ncbi.nlm.nih.gov/35385574
Autor:
Su Huang, Riyao Yang, Cai Huang, Saroja Putrevu, Nathan S. Fay, Kimberly Wright, Mohd Saif Zaman, Betty Huang, Bo Wang, Meredith Wright, Yanan Wang, Xuefei Tian, Yue Liu
Publikováno v:
Cancer Research. 82:1087-1087
Background: Cancer immunotherapy has transformed cancer therapy. In particular, blockade of the PD-L1/PD-1 axis with PD-1 or PD-L1 antibodies has achieved successful and durable treatment outcomes in some patients across a variety of cancer types. Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::158901cccc52a2e9729767e983677abe
https://doi.org/10.1158/1538-7445.am2022-1087
https://doi.org/10.1158/1538-7445.am2022-1087
Autor:
Riyao Yang, Linlin Sun, Ching-Fei Li, Yu-Han Wang, Weiya Xia, Boning Liu, Yu-Yi Chu, Laura Bover, Long Vien, Mien-Chie Hung
Publikováno v:
Journal of Biological Chemistry. 298:101821
Antibodies that target immune checkpoint proteins such as programmed cell death protein 1, programmed death ligand 1, and cytotoxic T-lymphocyte-associated antigen 4 in human cancers have achieved impressive clinical success; however, a significant p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7130d95f001e3bda97d4f80cd36b79c5
https://doi.org/10.1016/j.jbc.2022.101821
https://doi.org/10.1016/j.jbc.2022.101821